In a patient with liver cancer and bilirubin of 5 mg/dL and a platelet count of 62 × 10⁹/L, is it safe to transfuse a single‑donor platelet unit?

Platelet Transfusion is NOT Recommended for This Patient

In a patient with liver cancer, bilirubin of 5 mg/dL, and a platelet count of 62,000/µL (62 × 10⁹/L), prophylactic platelet transfusion is not indicated and should not be performed. This platelet count is above the threshold where transfusion would be considered, and there is no evidence that transfusion improves outcomes in this setting.

Evidence-Based Rationale

Guideline Recommendations for Liver Disease

The most recent and authoritative guidance comes from the 2022 EASL (European Association for the Study of the Liver) Clinical Practice Guidelines 1. These guidelines provide clear thresholds:

For patients with cirrhosis/liver disease undergoing invasive procedures:

• Platelet count >50 × 10⁹/L: Platelet transfusion is NOT recommended (strong recommendation) 1
• Platelet count 20-50 × 10⁹/L: Transfusion should not be routinely performed but may be considered case-by-case for high-risk procedures where local hemostasis is impossible 1
• Platelet count <20 × 10⁹/L: Transfusion should be considered case-by-case for high-risk procedures 1

Your Patient's Situation

Your patient has a platelet count of 62 × 10⁹/L, which is:

• Above the 50 × 10⁹/L threshold where transfusion is explicitly not recommended
• In a range where in vitro evidence shows preserved platelet-dependent thrombin generation 1
• Sufficient for hemostasis due to compensatory mechanisms in liver disease (elevated von Willebrand factor, increased activated platelets) 1

Why Transfusion is Not Beneficial

1. No evidence of efficacy: Studies show that prophylactic platelet transfusion in cirrhotic patients with thrombocytopenia does not improve hemostatic potential. One study showed transfusion increased platelet count slightly (39 to 52 × 10⁹/L) but had no significant effect on hemostatic tests 1

2. Potential harm without benefit: Platelet transfusions carry risks including:

   • Transfusion reactions
   • Alloimmunization leading to refractoriness
   • Bacterial contamination
   • Unnecessary resource utilization 1

3. Lack of supporting evidence: The EASL guidelines explicitly state that "no studies have specifically evaluated whether the infusion of platelet concentrates decreases the rate of procedure-related clinically relevant bleeding" in this population 1

Clinical Decision Algorithm

For a patient with liver cancer and platelet count 62 × 10⁹/L:

1. Is the patient actively bleeding?

   • No → Do not transfuse
   • Yes → Manage bleeding with local hemostatic measures first; consider transfusion only if bleeding cannot be controlled

2. Is a high-risk invasive procedure planned?

   • No → Do not transfuse
   • Yes → Proceed with procedure without prophylactic transfusion if platelet count >50 × 10⁹/L

3. Can local hemostasis be achieved if bleeding occurs?

   • Yes → Do not transfuse prophylactically
   • No AND platelet count 20-50 × 10⁹/L → Consider case-by-case

Important Caveats

• The bilirubin level of 5 mg/dL indicates significant liver dysfunction but does not change the platelet transfusion threshold
• Single-donor platelets (apheresis platelets) versus pooled random-donor platelets: If transfusion were indicated, single-donor platelets reduce donor exposure and may decrease alloimmunization risk 2, 3, but this is irrelevant when transfusion is not indicated
• The 2018 ASCO guidelines for cancer patients recommend a threshold of 50 × 10⁹/L for major surgery 4, which aligns with the EASL recommendations

Bottom Line

Do not transfuse this patient. A platelet count of 62 × 10⁹/L is adequate for hemostasis in liver disease, and prophylactic transfusion provides no benefit while exposing the patient to unnecessary risks. Reserve platelet transfusion for active bleeding that cannot be controlled with local measures, or for high-risk procedures in patients with counts <50 × 10⁹/L where local hemostasis is impossible.